Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 19.3%

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 10,541,776 shares, a growth of 19.3% from the January 29th total of 8,839,652 shares. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days. Approximately 15.1% of the shares of the stock are short sold. Approximately 15.1% of the shares of the stock are short sold. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days.

Inhibikase Therapeutics Trading Up 2.1%

NASDAQ IKT traded up $0.04 on Wednesday, hitting $1.95. 1,757,567 shares of the company were exchanged, compared to its average volume of 1,861,127. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $2.58. The firm’s 50 day simple moving average is $1.77. The company has a market cap of $146.60 million, a P/E ratio of -5.00 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on IKT shares. Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a report on Saturday, December 27th. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Friday, December 26th. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Finally, Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Inhibikase Therapeutics presently has a consensus rating of “Buy”.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.